- The FDA approved a new drug, Kadcyla, that kills cancer cells more effectively while potentially reducing side effects.
- Men with high-risk prostate cancer undergoing hormone therapy live just as long whether they receive treatment for 18 months or 36 months.
- African-Americans and people living in poverty are more likely to present with an emergency colorectal cancer diagnosis.
- Daily use of a multivitamin reduced total cancer incidence in men tracked for more than a decade.
Category Archives: In the News
Blog Buzz: February 15 – February 22
The New York Genome Center has a nice round up post on Clinical Genomics talks from day two of the Advances in Genome Biology and Technology conference. You can see all their posts from the meeting on their website.
The FDA has approved TDM-1 for breast cancer, according to coverage from Reuters. Here is a brief item from Forbes about the drug and its cost, A Triumph in Breast Cancer–And Another Expensive Drug. (A number of people on Twitter have commented that the brand name is Kadcyla a bit close to Kalydeco, a drug used in the treatment of cystic fibrosis.)
On Thursday, the NIH announced a new US policy for research with potentially risky subjects requiring stricter controls, such as H5N1. The LA Times has coverage, and this post from the Nature News Blog includes a number of helpful links, as well as official opportunities for public comment on the policy related to this type of research, referred to as “dual-use research of concern”.
The Washington Post WonkBlog explains a new regulation on how insurance companies must cover colonoscopies under the Affordable Care Act.
MSKCC in the News: February 14 – February 20
- Westchester Medical Center (WMC) has announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with MSKCC, whose staff will provide outpatient cancer care and infusion services.
- Dr. Michael J. Morris of MSKCC was quoted in a New York Times article about a new study that found that men with high-risk prostate cancer treated with only 18 months of hormone therapy live just as long as those treated for a more standard 36 months.